CD3-HM505B-100μg / 询价
CD3-HM505B-500μg / 询价
CD3-HM505B-500μgx2 / 询价
- 客服电话
- 技术支持
Biotinylated Human CD3E&CD3D/CD3 epsilon&CD3 delta Protein
Recombinant Biotinylated Human CD3E&CD3D/CD3 epsilon&CD3 delta Protein is expressed from HEK293 with hFc tag and Avi tag at the C-Terminus.It contains Asp23-Asp126(CD3E) & Phe22-Ala105(CD3D) [Accession | P07766(CD3E)&P04234(CD3D)].
The protein has a predicted MW of 40 kDa (CD3E) and 35.4 kDa (CD3D). Due to glycosylation,the protein migrates to 48-60 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human CD3E&CD3D on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CD3E&CD3D was greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CD3E&CD3D, hFc Tag at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for OKT3, mFc Tag with the EC50 of 42.1ng/ml determined by ELISA.
T-cell surface glycoprotein CD3 epsilon&CD3 delta chain, also known as CD3E&CD3D , are single-pass type I membrane proteins.When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain.
CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon
(1)Penaranda C , Tang Q , Bluestone J A. Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells[J]. The Journal of Immunology, 2011, 187(4):2015-2022.
